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ABSTRACT
Although androgen deprivation therapy (ADT) serves as the primary treatment 
option for localized or metastatic prostate cancer, most cases eventually develop 
into castration-resistant prostate cancer (CRPC). However, androgen receptor 
(AR) continues to be functional in CRPC through various mechanisms, including 
the development of AR splicing variants, especially ARV7. Since it lacks the ligand 
binding domain but retains the intact DNA binding domain, ARV7 is constitutively 
active, which makes ARV7-positive prostate cancer responsive to neither abiraterone 
nor enzalutamide. In this study, we explored the effect of resveratrol on ARV7 
transcriptional activity and the potential for development of resveratrol as a treatment 
for ARV7-positive prostate cancer. First, we ectopically expressed ARV7 in PC3 cells, 
an AR-negative prostate cancer cell line, and demonstrated that resveratrol is capable 
of inhibiting ARV7 transcriptional activity by downregulating ARV7 protein levels. Of 
note, resveratrol does not affect the mRNA levels of ARV7 nor its nuclear translocation. 
Next, we demonstrated that resveratrol is capable of downregulating the levels of the 
endogenously expressed ARV7 as well as AR target gene mRNAs in 22RV1 prostate 
cancer cells. Mechanistically, resveratrol downregulates ARV7 by enhancing ARV7 
polyubiquitination and subsequent proteasome-mediated degradation. These findings 
suggest that resveratrol could be a potential treatment for ARV7-positive CPRC.
INTRODUCTION
Prostate cancer is one of the most frequently 
diagnosed cancers and the second leading cause of 
cancer-related death in men in the United States [1, 2]. 
In addition, the incidence of prostate cancer is increasing 
significantly due to the effects of the western lifestyle and 
the increase of the aging population [3, 4]. Androgen-
deprivation therapy (ADT) is the first line of defense, and 
most of the time, an effective treatment for localized and 
metastasized prostate cancers. However, a quarter of these 
patients suffer relapse of the disease and most prostate 
cancers eventually become castration resistant (CRPC) 
with tumor recurrence and metastasis within a period of 
6 months to 3 years [1, 5, 6]. Furthermore, in the less 
developed countries, most prostate cancers are diagnosed 
at advanced stages [7]. Therefore, prostate cancer is a big 
burden for both developed and developing countries, and 
thus understanding of the mechanisms underlying prostate 
cancer development and progression as well as developing 
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efficacious therapies for prostate cancer, especially CRPC, 
is urgently needed. 
The androgen/androgen receptor (AR) axis 
plays crucial roles in both normal prostate function 
and the development of prostate diseases including 
prostate cancer. Depleting androgen or inhibiting AR 
transcriptional activity has been proven to be effective in 
prostate cancer treatment. Multiple lines of evidence show 
that re-establishment of functional AR transcriptional 
activity is a critical event in the emergence of CRPC. 
Both abiraterone and enzalutamide are currently the best 
agents for CYP17 and AR inhibition, respectively. These 
drugs either individually or in combination can extend the 
survival of patients with CRPC. However, development of 
resistance to these drugs is inevitable [8, 9] for a subgroup 
of CRPC expressing different AR variant characterized 
with the loss of the c-terminal domain but maintaining 
both N-terminal transcriptional domain and the ligand 
binding domain [10, 11]. Reports from different groups 
showed that prostate cancer cells expressing constitutively 
active AR splicing variants respond to neither of these 
reagents [8, 12, 13]. 
More recent data suggest that among the 22 AR 
slicing variants identified so far [14], ARV7 is not only 
the most prevalent [15, 16] but also most relevant to the 
development of CRPC [17]. ARV7 is generated from 
alternative splicing of the third intron of the AR pre-
mRNA, which creates a cryptic exon and leads to the 
formation of a truncated AR with a stretch of 16 extra 
amino acids unique for this particular variant. Although 
ARV7 is expressed in the presence of AR-full length 
mRNA and most of the time co-expressed with full-length 
AR, results from different labs showed not only that the 
positivity but also the intensity of ARV7 are enhanced 
by hormonal therapies. For example, Antonarakis et al 
[18] reported that ARV7 was detected in 55% of patients 
who had received prior abiraterone versus those who had 
not; enzalutamide treatment increased ARV7 expression 
from 15% to 50%, suggesting that ADT can enhance the 
expression of ARV7 to a certain degree. More importantly, 
clinical responses were inversely correlated with ARV7 
expression: 68% of ARV7-negative patients showed PSA 
response when treated with abiraterone comparing to 
0% response in the ARV7-positive group. When treated 
with enzalutamide, 53% and 0% of patients showed 
PSA response in the ARV7-negative and ARV7-positive 
groups, respectively [17]. Therefore, the identification and 
application of agents capable of targeting ARV7 would be 
a valuable strategy in treatment of CRPC.
Resveratrol (RSV, 3,4′,5-trihydroxystilbene) is 
one of the well-documented reagents in prostate cancer 
chemoprevention [19]. Chemically, RSV is a polyphenol 
transhydroxystilbene found at high levels in grapes 
and red wines [20]. Animal studies have demonstrated 
that RSV is rapidly absorbed by the gut and distributed 
into different tissues [21, 22]. Since the first reported 
cancer chemopreventive effects of RSV in 1997 [23], 
both epidemiological and case-controlled studies have 
demonstrated that RSV and/or consumption of high RSV-
containing foods and drinks can reduce prostate cancer 
incidences [24]. There are multiple lines of evidence 
shown that RSV exerts its effects on prostate cancer in 
an AR-dependent manner [25–27] through involvement 
of the regulation of AR expression and function [28, 29]. 
It has been well established that RSV downregulates the 
expressions of both AR and AR target genes [30–32]. 
Harada et al. reported that RSV represses AR target gene 
expression, at least partially, by enhancing AR degradation 
in a time- and dose-dependent manner [33]. We have 
demonstrated that RSV regulates AR target gene expression 
by repressing AR transcriptional activity without affecting 
AR nuclear translocation nor DNA binding [34].
In this report, we showed that RSV is capable of 
inhibiting ARV7-mediated transcription of AR target 
genes in prostate cancer cells by downregulating the 
protein levels of both ectopically and endogenously 
expressed ARV7 without affecting either mRNA levels nor 
its nuclear translocation. Mechanistically, RSV enhances 
polyubiquitination and subsequent degradation of ARV7 
in a proteasome-dependent manner. 
RESULTS
Ectopically expressed ARV7 is capable of 
upregulating PSA in PC-3 cells
Since it has been reported that the transcriptional 
activity of ARV7 is partially dependent on the expression 
of full-length AR [35], we wanted to determine if ARV7 
is capable of regulating AR target gene expression in a 
full-length AR-free prostate cancer cellular environment. 
To do so, we decided to ectopically express ARV7 in 
PC3 cells, a prostate cancer cell line expressing neither 
full-length AR nor ARV7, by transiently transfection of 
plasmids expressing ARV7. To confirm that PC3 cells are 
ARV7- and PSA-negative, we conducted RT-PCR with 
mRNAs obtained from two prostate cancer cell lines PC3 
and LNCaP. Since LNCaP cells were known AR-positive 
prostate cancer cells and express readily detectable PSA, 
we chose to use LNCaP cells as the positive control. 
As expected, both full-length AR and PSA were readily 
detectable by RT-PCR but with undetectable level of 
ARV7 in LNCaP cells.  However, none of the full-
length AR, PSA or ARV7 was expressed in PC3 cells 
(Figure 1A). Then, PC3 cells were transiently transfected 
with or without plasmid expressing ARV7 followed by 
RT-PCR (Figure 1B) and western blot (Figure 1C) assays. 
As shown in Figure 1B and 1C, ARV7 was successfully 
transfected and expressed in PC3 cells, as evidenced 
by the fact that ARV7 mRNA (Figure 1B) and protein 
(Figure 1C) were only detected in the cells transfected 
with ARV7-expressing plasmid. In addition, both RT-
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PCR (Figure 1D) and quantitative PCR (Figure 1E) 
demonstrated that the ectopically expressed ARV7 is 
capable of upregulating AR target gene PSA. These data 
also suggest that ARV7 can function without the full-
length AR.
RSV inhibits ARV7 transcriptional activity by 
downregulating its protein levels 
To determine if RSV can inhibit ARV7 
transcriptional activity, we treated PC3 cells transfected 
with ARV7-expressing plasmid with different 
concentrations of RSV for 24 hours. Total mRNAs were 
purified and the PSA levels serving as an indicator of the 
ARV7 transcriptional activity were estimated by RT-PCR 
(Figure 2A) and qPCR (Figure 2B). Figure 2A and 2B 
show that ARV7 transcriptional activity is inhibited by 
RSV in a dose-dependent manner. Next, we conducted 
RT-PCR and western blot assays to determine if RSV 
downregulates ARV7 transcriptional activity by repressing 
its mRNA or protein levels. As shown in Figure 2C, ARV7 
mRNA levels were not affected by RSV treatment but 
protein levels were downregulated by RSV in a dose-
dependent manner (Figure 2D). These data collectively 
demonstrated that RSV is capable of inhibiting ARV7 
transcriptional activity in a dose-dependent manner and 
mechanistically downregulating ARV7 protein levels 
without affecting mRNA level.
RSV does not affect ARV7 nuclear translocation
Upon the binding of androgens, the full-length 
AR translocates to the nucleus from the cytoplasm and 
interacts with the androgen responsive element (ARE) to 
regulate AR target gene expression. Therefore, targeting 
AR’s nuclear translocation can be used as a strategy in 
repressing AR transcriptional regulation. We wanted to 
determine if RSV represses ARV7 transcriptional activity 
by inhibiting its nuclear translocation. To this end, we 
treated the PC3 cells transfected with ARV7-expressing 
plasmid with or without 100 µM RSV for 24 hours and 
conducted immunostaining with antibody against the 
N-terminus of AR, which is able to recognize both full-
length AR and ARV7. Immunostaining of LNCaP cells 
treated with the synthesized androgen R1881 serves as 
experimental control. As shown in Figure 3, although 
RSV treatment reduced the total ARV7 levels dramatically 
(consistent with changes observed in Figure 2), the 
expressed ARV7 was mainly found in the nuclei whether 
the cells were treated with or without RSV. These data 
suggest that RSV inhibits ARV7 transcriptional activity 
by downregulating ARV7 protein levels without affecting 
its nuclear translocation. In addition, since ARV7 was 
ectopically expressed in PC3 cells without the full-length 
AR, we also conclude that the nuclear translocation of 
ARV7, at least for the ectopically expressed form, is 
independent of the full-length AR.
RSV downregulates endogenously expressed 
ARV7 without affecting full-length AR
After demonstrating RSV’s effects on the 
ectopically expressed ARV7, we wanted to determine 
if RSV has similar effects on ARV7 endogenously 
expressed in prostate cancer cells. We chose to use the 
22RV1 cell line because it represents the CRPC prostate 
cancer cells and both full-length AR and ARV7 were 
expressed endogenously in these cells. First, we treated 
22RV1 cells with increasing concentrations of RSV 
for 24 hours, and the cell viabilities were estimated by 
Figure 1: Ectopically expressed ARV7 in PC-3 cells is capable of upregulating PSA. (A) RT-PCR with mRNAs from both 
LNCaP and PC-3 cells with primers specific for full-length AR, ARV7, PSA and GAPDH. (B–C) PC-3 cells were transiently transfected 
with or without plasmid expressing ARV7, and RT-PCR (B) or WB (C) was conducted. (D–E) RT-PCR (D) or qPCR (E) was conducted 
with mRNAs from PC-3 cells transfected with or without ARV7.
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Figure 2: RSV inhibits ARV7 transcriptional activity by downregulating ARV7 protein levels. PC-3 cells were transiently 
transfected with plasmid expressing ARV7 and treated with different concentrations (0–100 µM) of RSV for 24 hours. Both RT-PCR (A) 
and qPCR (B) were conducted to estimate the effect of RSV on the mRNA levels of PSA; RT-PCR and WB were conducted to estimate the 
levels of ARV7 mRNA (C) and protein (D).
Figure 3: PC-3 cells were transiently transfected with plasmid expressing ARV7 and treated with or without RSV 
for 24 hours. LNCaP cells were treated with 10 nM R1881 for 24 hours. Immunostaining was conducted to determine the subcellular 
localizations of AR and ARV7. Scale bar: 100 µm.
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counting the number of live cells. As shown in Figure 4A, 
RSV is capable of inhibiting 22RV1 cell growth in a 
dose-dependent manner. Then, we conducted RT-PCR 
to estimate RSV’s effects on the mRNA levels of PSA 
and ARV7. Figure 4B (RT-PCR) and 4C (qPCR) show 
that RSV is able to dose-dependently repress PSA levels 
without affecting the levels of ARV7 mRNA. In addition, 
we have conducted RT-PCR on another three potential 
ARV7 target genes (UBE2C, TMPRSS2 and FKBP51) to 
estimate RSV’s effect on ARV7 transcriptional activity. 
Supplementary Figure 1 show that the mRNA levels of all 
of them were downregulated by RSV. However, western 
blotting assays demonstrated that the ARV7 protein levels 
were dose-dependently downregulated by RSV (Figure 4D 
and 4E). Of note, the protein levels of the full-length AR 
were not affected by RSV treatment in these cells. These 
data suggest that resveratrol is capable of downregulating 
ARV7 protein levels without affecting the full-length AR 
protein level in 22RV1 cells. 
RSV enhances ARV7 protein degradation in 
prostate cancer cells
Next, we wanted to understand the mechanism 
in RSV-induced ARV7 protein downregulation. To 
this end, we treated 22RV1 cells with 50µM/mL of 
cyclohexmide alone or in combination with 100µM 
RSV for different time periods. Cells were collected at 
different time points and both full-length AR and ARV7 
protein levels were determined by western blotting assays 
with antibody against either AR or actin. As shown in 
Figure 5A and 5B, ARV7 protein levels decreased in a 
time-dependent manner in either treatment but the full-
length AR and actin levels were relatively unchanged 
during the observed period. However, compared to the 
cells treated with cyclohexmide alone, RSV appears to 
be able to reduce ARV7 stability because ARV7 levels 
decreased dramatically in the cells treated with the 
combination of RSV and cyclohexamide. The intensities 
of the protein bands were estimated by ImageJ program 
and the estimated full-length AR and ARV7 levels were 
normalized with actin, and the normalized levels in both 
treatments were plotted (Figure 5C). It is clear that RSV 
is capable of enhancing ARV7 degradation by reducing 
the half-life of ARV7 from about 4 hours (CHX only) to 
2 hours (CHX+RSV). Interestingly, the protein levels of 
full-length AR were not affected significantly.  
RSV enhances ARV7 polyubiquitination and 
subsequent degradation
To test if RSV enhances ARV7 degradation through 
the polyubiquitination-mediated proteasome pathway, 
we treated the 22RV1 cells with RSV or MG132 alone 
Figure 4: RSV inhibits prostate cancer growth and downregulates ARV7 in 22RV1 cells without affecting full-length 
AR. 22RV1 cells were treated with different concentrations (0–100 µM of RSV for 24 hours and the number of viable cells were estimated 
through cell counting (A). The mRNA levels of PSA and ARV7 were estimated by RT-PCR (B) and q-PCR (C). The protein levels of ARV7 
and full-length AR were estimated by western blotting assays (D and E).
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or in combination for 24 hours. ARV7 protein levels 
were estimated by western blot assays with p53 as the 
experimental control. As shown in Figure 6A the p53 
level was elevated when the cells were treated with either 
RSV or MG132 alone or in combination. However, the 
ARV7 levels were not significantly affected under the 
same conditions. In addition, treatment of the cells with 
RSV alone reduced the ARV7 level as seen previously. 
These data suggest that RSV’s effect on ARV7 degradation 
is either not through the polyubiquitination-mediated 
pathway or somehow different from the mechanism 
used by p53 degradation.  To determine if RSV affects 
polyubiquitination in general, we conducted western 
blot assay using antibody against ubiquitin. As shown in 
Figure 6B, although the overall levels of polyubiquinated 
proteins in these cells were not affected by RSV treatment 
alone (lane 2), RSV is capable of enhancing the MG132 
inhibited protein degradation (lane 3). As expected, 
when the cells were treated with MG132 alone the 
polyubiquitinated protein levels were elevated (lane 4). 
These data suggest that RSV is capable of enhancing 
protein ubiquitination but the polyubiquitinated proteins 
were quickly degraded in the absence of MG132. 
We then treated 22RV1 cells with RSV or MG132 
alone or in combination for 24 hours and conducted 
immunoprecipitation with antibody against AR 
N-terminus which is able to recognize both full-length 
AR and ARV7. Normal IgG was used as a negative 
control. The precipitated proteins were analyzed by 
western blotting assays. As shown in Figure 6C, ARV7 
was readily detectable in the inputs, and both the full-
length AR and ARV7 were successfully precipitated by 
the specific antibody; the normal IgG only nonspecifically 
precipitated some background levels of proteins. Of note, 
either RSV or MG132 alone or in combination failed to 
affect ARV7 levels significantly. However, when the same 
blot was stripped and re-probed with antibody against 
ubiquitin (Figure 6D), we found that MG132 alone was 
able to increase the levels of polyubiquitinated ARV7 
and this effect was synergized with RSV. Nevertheless, 
the levels of polyubiquitinated ARV7 in the cells treated 
with RSV alone were about the same as those of the 
control. These data altogether demonstrate that RSV 
is capable of enhancing ARV7 polyubiquitination but 
the polyubiqitinated ARV7 is quickly degraded (RSV 
alone) by the proteasome system because inhibition of 
proteasome-mediated protein degradation by MG132 
leads to the accumulation of polyubiquitinated ARV7 
(RSV+MG132).
Given the fact that 22RV1 cells express both full-
length AR and ARV7 and there are potential interactions 
between them. 
In order to demonstrate that RSV mediates 
ARV7 degradation by enhancing polyubiquitination, 
similar experiments were done with the exogenously 
expressed ARV7 in PC3 cells. First, we conducted 
immunoprecipitation of the exogenously expressed ARV7 
in PC3 cells treated with RSV and MG132 alone or in 
combination (Supplementary Figure 2) and found that RSV 
downregulated ARV7, MG132 failed to counteract RSV 
effect. Supplementary Figure 3 shows that, similar to was 
on endogenously expressed ARV7, the polyubiquitination 
of the exogenously expressed ARV7 is enhanced by RSV. 
To further that RSV effect on ARV7 degradation is through 
polyubiquitination pathway, we estimated the levels of 
ARV7 and overall protein ubiquitination in 22RV1 cells 
treated with either RSV or PYR-41 (an inhibitor of the 
E1 enzyme in the ubiquitination pathway) alone or in 
combination.  Supplementary Figure 4A shows that the 
total protein levels were comparable among the differently 
treated samples. However, WB results (Supplementary 
Figure 4B) indicate that RSV is capable of enhancing 
Figure 5: Effect of RSV on ARV7 protein degradation. 22RV1 cells were cultured in growth media with 50 nM CHX along (A) or 
in combination with 100 µM RSV (B) and collected at different time points (0–8 h). Western blotting assays were conducted with antibodies 
against ARV7 and actin. The intensities of the protein bands were estimated by Image-J and normalized with that of actin and plotted (C).
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polyubiquitinated (comparing lanes 1 and 2) and the E1 
enzyme inhibitor PYR-41 effectively repressed RSV-
induced poly-ubiquitination (comparing lanes 2 and 3).
DISCUSSION
Given the fact that [1] ARV7 positivity strongly 
correlates with both CRPC status and poor prognoses for 
prostate cancer patients diagnosed at late stages [36], and [2] 
ARV7-positive prostate cancers have proven to be resistant 
to almost all currently available prostate cancer drugs and 
therapies [37–39], either reducing the level or inhibiting the 
activity of ARV7 would be plausible therapeutic strategies 
for ARV7-positive CRPC. Based on this, we evaluated if 
RSV is able to affect ARV7 and found that RSV is not only 
capable of downregulating the levels of ARV7 but also 
of repressing the expression of its target genes in prostate 
cancer cells. Based on our observations, we proposed a 
working model (Figure 7) to explain the RSV-enhanced 
polyubiquitination and subsequent degradation of ARV7 
in prostate cancer cells. Without the presence of protein 
degradation inhibitor MG132, RSV-enhanced ARV7 
polyubiqitination is followed by quick degradation. In the 
presence of MG132, ARV7 is polyubiquitinated but fails 
to be degraded and therefore the level of polyubiquitinated 
ARV7 is increased. However, under either condition, the 
non-ubiquitinated ARV7 is reduced by RSV.
In order to determine if RSV can target ARV7 
specifically, we first tested the effects of RSV on the 
ectopically expressed ARV7 in PC3 cells. Since PC3 
cells express neither full-length AR nor AR target PSA 
(Figure 1), this enabled us to determine the effects of 
RSV on the ectopically expressed ARV7 in a prostate 
cancer cellular environment but without the effects of 
the endogenously expressed ARs. We demonstrated that 
RSV is capable of downregulating both ARV7 protein 
levels and its transcriptional activity without affecting its 
mRNA levels (Figure 2). Note, the transcription of ARV7 
in this system was controlled by the CMV promoter and 
since the level of ARV7 mRNA is not affected by RSV, 
it suggests that RSV-mediated downregulation of ARV7 
protein level is likely not through an effect on ARV7 
mRNA stability. The same findings were confirmed with 
the endogenously expressed ARV7 in 22RV1 prostate 
cancer cells (Figure 4). Although there are some reports 
suggesting that a functional ARV7 depends on the 
existence of the full-length AR [35], our results suggest 
that ARV7 can regulate AR target gene PSA in a full-
length AR-independent manner. In addition, even though it 
does not contain the canonical nuclear translocation signal, 
ARV7 is mainly expressed in the nuclei of the prostate 
cancer cells, and RSV appears not to affect ARV7 nuclear 
translocation (Figure 3). 
It has been well documented that RSV can inhibit 
the function of the full-length AR through different 
mechanisms, including enhancement of AR degradation. 
However, we found that RSV is capable of downregulating 
ARV7 protein levels without affecting the full-length AR 
in 22RV1 cells. This observation leads us to speculate that 
RSV exerts its degradation effects on the full-length AR 
Figure 6: Effect of RSV on polyubiquitination in prostate cancer cells. (A–B) 22RV1 cells were treated with or without RSV 
and MG132 for 24 hours. WB was conducted to estimate the levels of ARV7, P53 (A) and ubiquitinated proteins (B). Lysates were used for 
immunoprecipitation with antibodies against AR or nonspecific IgG, and the precipitated proteins were analyzed by WB with antibodies 
against AR (C), ubiquitin or tubulin (D).
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and ARV7 through different mechanisms. This speculation 
has been further substantiated by the fact that the half-life 
of ARV7 but not that of the full-length AR was shortened 
by RSV in 22RV1 cells. Given the fact that ARV7 has a 
sequence identical to the full length AR except for the 
extra 16 amino acids at its C-terminus, we speculate that 
this short sequence in itself or together with part of the 
rest of ARV7 plays an essential role in RSV-mediated 
ARV7 degradation. In addition, this short sequence may 
also be responsible for the nuclear translocation of ARV7. 
However, bioinformatics analyses of this short sequence 
(unpublished data) failed to identify any motif particularly 
related to protein degradation or nuclear translocation. 
It has been reported recently that by screening a drug 
library containing about 1120 FDA-approved chemicals 
with an unbiased strategy, the well-studied anti-helminthic 
drug niclosamide was found to be able to repress ARV7 
recruitment to the PSA promoter, resulting in decreased PSA 
transcription. Further exploration found that niclosamide 
utilizes a proteasome-dependent pathway to degrade ARV7 
protein which resulted in decreased ARV7 protein level but 
without affecting its mRNA level [40]. Therefore, the authors 
suggest that niclosamide alone or in combination with other 
anti-cancer drugs could be used for the treatment of CRPC. 
However, niclosamide has been used as an anti-helmithic 
drug with multiple issues unrelated to prostate cancer. 
Therefore, treating prostate cancers with niclosamide may 
lead to some undesirable side effects, and thus making this 
drug a relatively unattractive therapeutic option for CRPC. 
Although RSV downregulates ARV7 in a similar manner as 
niclosamide, RSV has not shown any side-effects but with 
multiple beneficial effects on skin disorders, type II diabetes, 
cardiovascular diseases, and obesity [41]. Therefore, RSV 
appears to be superior to niclosamide in downregulating 
ARV7. However, the drawback to RSV as a potential 
therapeutic option is its relatively low bioavailability 
in human tissues [42]. On the other hand, pterostilbene 
(PTER) is a structural analog of RSV with greater tissue 
bioavailability than RSV [43]. Our preliminary data suggest 
that PTER functions similarly to RSV in regard to ARV7 
(unpublished data) and once this is fully confirmed, PTER 
could be an even better drug to target ARV7 in CRPC. 
In addition, there are other strategies targeting the levels 
of ARV7. For example, Jin et al. found that NF-kB can 
increase ARV7 expression in prostate cancer cells. They 
also found that when NF-kB signaling pathway is blocked, 
both ARV7 mRNA and protein levels were down-regulated. 
Furthermore, blocking NF-kB signaling makes CRPC cells 
become ADT-responsive [44]. Therefore, a combination of 
therapies targeting ARV7 mRNA levels (such as blocking 
NF-kB) with RSV and/or PTER could be more efficacious 
in the treatment of ARV7-positive CRPC.
In summary, we demonstrated that RSV is capable 
of downregulating both ectopically and endogenously 
expressed ARV7 in prostate cancer cells without affecting 
the mRNA levels or the nuclear translocation of ARV7. 
Mechanistically, RSV enhances ARV7 polyubiquitination 
and subsequent proteasome-mediated degradation. These 
observations suggest that RSV possesses a great potential 
to become a treatment for ARV7-positive CPRC.
MATERIALS AND METHODS
Cell lines and chemicals
DMSO, resveratrol (RSV), MG132, R1881 were 
all purchased from Sigma-Aldrich (St. Louis, MO). 
Resveratrol stock solution (1 mM) was made by dissolving 
Figure 7: Model of RSV enhancing polyubiquitination-mediated ARV7 degradation.
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RSV in DMSO and stored at −20°C in the dark. Antibodies 
against both full-length AR and ARV7 (N-20), ß-tubulin, 
GAPDH ubiquitin and normal rabbit IgG were purchased 
from Santa Cruz Biotechnologies and all stored at 4°C. 
The ARV7 expressing plasmid was a kind gift from Dr. 
Lu’s lab (The James Buchanan Brady Urological Institute 
and Department of Urology, The Johns Hopkins School 
of, Baltimore, MD 21287, USA). LNCaP, 22RV1 and 
PC3 cells were obtained from American Type Culture 
Collection (ATCC). PC3 cells were cultured in Ham’s 
F-12 with L-glutamine, 10% premium FBS, and 1% 
Antibiotic-Antimycotic.  LNCap and 22RV1 cells were 
maintained in RPMI 1640 medium supplemented with 
10% (wt/vol) fetal bovine serum (FBS) and 1% antibiotics 
at 37°C under 5% CO2. 
Immunostaining
Cells were grown on glass cover slides, fixed with 
3.5% formaldehyde for 15 minutes, and permeabilized 
with 0.02% NP-40 for 1 minute. After blocking with 
5% goat serum for 1 hour, cells were incubated with 
anti-AR antibodies (N20) for 2 hours. The slides were 
then incubated in donkey anti-rabbit immunoglobin G 
conjugated with Alexa Fluor 594 for 2 hours. One drop 
of mounting medium (Fisher Scientific) was added onto 
each slide and the images were visualized by conventional 
microscopy.
Transient transfection
ARV7 expressing plasmid was transiently 
transfected into PC3 cells using Lipofectamine 2000 
reagent according to the manufacturer’s instructions 
(Invitrogen). Transfected cells were allowed to recover 
for 6 hours before replacing with regular growth media 
followed by specific treatments for designated time 
periods. Cells were harvested and used for specific assays. 
All experiments were conducted in triplicate.
RNA isolation, RT-PCR and qPCR
Total RNA was isolated using the RNeasy mini kit 
(Qiagen) according to the manufacturer’s specifications. 
Total RNA from each sample was reverse-transcribed with 
random primers using a StrataScript reverse transcriptase 
kit (Stratagene) followed by either semi-quantitative 
or real-time PCR. Our standard PCR procedures are as 
follows: in a 25 µl reaction, DNA was denatured at 94°C 
for 2 min and followed by 30 cycles of 94°C for 45sec; 
62°C for 45sec and 72°C for 45sec. After the last cycle, 
reactions were incubated for an additional 5 min at 72°C 
to ensure that all DNA strands were extended to the ends. 
PCR products were separated by electrophoresis on 1% 
agarose gel and visualized under UV light. The intensities 
of DNA bands were estimated by the Image-J program. 
For qPCRs, the SYBR Premix Ex Taq II (Tli RNase H 
Plus) Kit was used per manufacturer’s recommendation.
Preparation of lysates and western blot
Whole cell lysates were obtained using the nuclear 
extract kit (Active Motif, California) according the 
manufacturer’s instructions. Protein concentrations were 
estimated by Bradford reagents and equal amounts of 
total proteins were separated on a 10% SDS-PAGE gel. 
The proteins were transferred to nitrocellulose membrane 
(BioRad, Hercules, CA) using the BioRad Blotting System 
according to the manufacturer’s instructions. Staining with 
Ponceau Red was done to confirm equal transfer of protein 
in all lanes. Blots were blocked for 2 hours in 5% non-fat 
milk and incubated with antiserum overnight at 4°C. After 
washing three times in TBST, the blots were incubated 
with the second conjugated antibody. The blots were 
detected by Supersignal West Pico Chemiluminescent Kit 
(Pierce). The membranes were then stripped and re-probed 
for either β-actin or GAPDH as internal controls.
Immunoprecipitation
Immunoprecipitation was done with cell lysates 
containing about 400 µg of protein in 100 µL. The 
lysates were pre-cleared with 25 µL of Pierce Protein 
A/G Magnetic Beads for 2 h. Lysate + beads were placed 
on the magnet for 2 min. The pre-cleared lysate was 
removed from the beads and 1µg of antibody was added. 
All samples (lysate + antibody) were incubated at 4°C 
overnight. The following day 100 µL of Pierce Protein 
A/G Magnetic Beads were added to the lysate + antibody, 
vortexed and rotated at 4°C for 2 h. All samples were 
placed on the magnet for 2 min and unbound lysate was 
removed. Beads were washed 3× with 100 µL washing 
buffer, vortexed and spun briefly before being placed on 
the magnet for 2 min. Proteins bound on the beads were 
eluted with 20 µL of 2× SDS sample buffer, and then 
boiled for 5 min before electrophoresis.
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